|
1
|
Kuehl WM and Bergsagel PL: Multiple
myeloma: Evolving genetic events and host interactions. Nat Rev
Cancer. 2:175–187. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rajkumar SV and Kumar S: Multiple myeloma:
Diagnosis and treatment. Mayo Clin Proc. 91:101–119. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chuang TT, Sallese M, Ambrosini G, Parruti
G and De Blasi A: High expression of beta-adrenergic receptor
kinase in human peripheral blood leukocytes. Isoproterenol and
platelet activating factor can induce kinase translocation. J Biol
Chem. 267:6886–6892. 1992.PubMed/NCBI
|
|
4
|
Loudon RP, Perussia B and Benovic JL:
Differentially regulated expression of the G-protein-coupled
receptor kinases, betaARK and GRK6, during myelomonocytic cell
development in vitro. Blood. 88:4547–4557. 1996.PubMed/NCBI
|
|
5
|
DeWire SM, Ahn S, Lefkowitz RJ and Shenoy
SK: Beta-arrestins and cell signaling. Annu Rev Physiol.
69:483–510. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gurevich EV and Gurevich VV: Arrestins:
Ubiquitous regulators of cellular signaling pathways. Genome Biol.
7:2362006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ek IJ and Otterstad HK: Health care for
the aged is better than its start! A status report from communities
in Vestfold in 1988–89. Fag Tidsskr Sykepleien. 78:26–28. 1990.(In
Norwegian). PubMed/NCBI
|
|
8
|
Kasiske BL: Relationship between vascular
disease and age-associated changes in the human kidney. Kidney Int.
31:1153–1159. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy
MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust
JA, et al: Improved survival in multiple myeloma and the impact of
novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stephens P, Edkins S, Davies H, Greenman
C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C, et al:
A screen of the complete protein kinase gene family identifies
diverse patterns of somatic mutations in human breast cancer. Nat
Genet. 37:590–592. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fong AM, Premont RT, Richardson RM, Yu YR,
Lefkowitz RJ and Patel DD: Defective lymphocyte chemotaxis in
beta-arrestin2- and GRK6-deficient mice. Proc Natl Acad Sci USA.
99:7478–7483. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chudziak D, Spohn G, Karpova D, Dauber K,
Wiercinska E, Miettinen JA, Papayannopoulou T and Bönig H:
Functional consequences of perturbed CXCL12 signal processing:
Analyses of immature hematopoiesis in GRK6-deficient mice. Stem
Cells Dev. 24:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nieto-Lluis C, Garcia-Pérez M and
Cabrera-Santos A: Influence of sympathetic withdrawal on early
postinfarction arrhythmias. Acta Physiol Hung. 70:351–356.
1987.PubMed/NCBI
|
|
15
|
Li YP: GRK6 expression in patients with
hepatocellular carcinoma. Asian Pac J Trop Med. 6:220–223. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taipale M, Krykbaeva I, Koeva M, Kayatekin
C, Westover KD, Karras GI and Lindquist S: Quantitative analysis of
HSP90-client interactions reveals principles of substrate
recognition. Cell. 150:987–1001. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakaya M, Tajima M, Kosako H, Nakaya T,
Hashimoto A, Watari K, Nishihara H, Ohba M, Komiya S, Tani N, et
al: GRK6 deficiency in mice causes autoimmune disease due to
impaired apoptotic cell clearance. Nat Commun. 4:15322013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Forbes S, Clements J, Dawson E, Bamford S,
Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA and
Stratton MR: COSMIC 2005. Br J Cancer. 94:318–322. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao S, Zhong L, Liu J, Feng J, Bian T,
Zhang Q, Chen J, Lv X, Chen J and Liu Y: Prognostic value of
decreased GRK6 expression in lung adenocarcinoma. J Cancer Res Clin
Oncol. 142:2541–2549. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Freedman NJ, Ament AS, Oppermann M,
Stoffel RH, Exum ST and Lefkowitz RJ: Phosphorylation and
desensitization of human endothelin A and B receptors. Evidence for
G protein-coupled receptor kinase specificity. J Biol Chem.
272:17734–17743. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vroon A, Heijnen CJ, Raatgever R, Touw IP,
Ploemacher RE, Premont RT and Kavelaars A: GRK6 deficiency is
associated with enhanced CXCR4-mediated neutrophil chemotaxis in
vitro and impaired responsiveness to G-CSF in vivo. J Leukoc Biol.
75:698–704. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Frank DA: STAT3 as a central mediator of
neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brocke-Heidrich K, Kretzschmar AK, Pfeifer
G, Henze C, Löffler D, Koczan D, Thiesen HJ, Burger R, Gramatzki M
and Horn F: Interleukin-6-dependent gene expression profiles in
multiple myeloma INA-6 cells reveal a Bcl-2 family-independent
survival pathway closely associated with Stat3 activation. Blood.
103:242–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bharti AC, Shishodia S, Reuben JM, Weber
D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M and Aggarwal BB:
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+
cells derived from multiple myeloma patients, and suppression of
these transcription factors leads to apoptosis. Blood.
103:3175–3184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nelson EA, Walker SR, Kepich A, Gashin LB,
Hideshima T, Ikeda H, Chauhan D, Anderson KC and Frank DA:
Nifuroxazide inhibits survival of multiple myeloma cells by
directly inhibiting STAT3. Blood. 112:5095–5102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pathak AK, Bhutani M, Nair AS, Ahn KS,
Chakraborty A, Kadara H, Guha S, Sethi G and Aggarwal BB: Ursolic
acid inhibits STAT3 activation pathway leading to suppression of
proliferation and chemosensitization of human multiple myeloma
cells. Mol Cancer Res. 5:943–955. 2007. View Article : Google Scholar : PubMed/NCBI
|
